Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia

Czech version

Authors: K. Sheardová ¹; J. Hort ²; R. Rusina ³; A. Bartoš ⁴; V. Línek ⁵; P. Ressner ⁶; I. Rektorová ^{1 *}
Authors‘ workplace: I. neurologická klinika LF MU, FN U sv. Anny, Brno ¹; Neurologická klinika 2. LF UK, FN Motol, Praha ²; Neurologická klinika FTN a IPVZ, Praha ³; Neurologická klinika 3. LF UK, FN Královské Vinohrady, Praha ⁴; Neurologická klinika 1. LF, VFN, Praha ⁵; Neurologické oddělení, Nemocnice s poliklinikou v Novém Jičíně ⁶
Published in: Cesk Slov Neurol N 2007; 70/103(5): 589-594
Category: Guidelines

*za Sekci kognitivní neurologie České neurologické společnosti ČLS JEP
Materiál vychází z EFNS guidelines [1] a je doplněn o některé aktuální poznatky a zmínky o českých specificích.

Overview

Background:
The aim of this guideline concerning therapy of dementia is to present a peer-reviewed, evidence-based statement in order to guide the practice of neurologists, geriatricians, psychiatrists, and other specialized physicians responsible for the care of patients with dementia. The main focus is the therapy of Alzheimer’s disease, but many of the recommendations apply to dementia disorders in general.

Methods:
The material is derived from revised EFNS guidelines and it is assembled with current findings and notations particular to Czech specifications. Evidence from original research reports, meta-analysis, and systematic reviews, published before January 2007 was considered in the writing the guidelines.

Results:
The task in writing this guideline proposes recommended treatment for Alzheimer’s disease, vascular dementia, Parkinson’s disease dementia, and dementia with Lewy Bodies. It also contains information about monitoring treatment, as well as treatment of behavioural and psychological symptoms in dementia.

Conclusion:
This guideline may contribute to the rational therapy proceeding in the most common dementia disorders according to evidence-based medicine.,

Key words:
Alzheimer’s disease – dementia – guidelines – therapy – vascular dementia

Sources

1. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B. EFNS. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007 14: 11-26.

2. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. British Medical Journal 1999; 318: 633-638.

3. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.

4. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Archives of Internal Medicine 1998; 158: 1021-1031.

5. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268.

6. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-2276.

7. Brodaty H, Cory-Bloom J, Potocnik FC, Tryen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders 2005; 20: 120-132.

8. NICE. Alzheimer’s disease - donepezil, rivastigmine and galantamine. NICE Tehnology Appraisal Guidance- No 19. 2001 www.nice.org.uk (accessed February 24, 2006).

9. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9): 1154-1166.

10. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.

11. Mohs RC, Doody RS, Morris JC et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-488.

12. Pirttala T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicenter trial. European Journal of Neurology 2004; 11: 734-741.

13. Rogers S, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. European Neuropsychopharmacology 2000; 10: 195-203.

14. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm A-L, Haglund A, Zhang R, Schindler R and the Donepezil Nordic Study Group. 3-year study of donepezil therapy in Alzheimer’s disease: Effects of early and continuous therapy. Dementia and Geriatric Cognitive Impairment 2006; 21: 353-361.

15. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-620.

16. Seltzer B, Zolnouni B, Nunez M et al. Donepezil „402“ study group. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Archives of Neurology 2004; 61: 1852-1856.

17. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2003;3 48: 1333-1341.

18. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Journal of the American Medical Association 2004; 291: 317-324.

19. Areosa SA, Sherriff F, McShane R. Memantine for dementia. The Cochrane Database of Systematic Reviews 2005; Issue 3. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub4.

20. Birks J, Grimley Evans J. Ginkgo Biloba for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2002; Issue 4. Art. No.: CD003120. DOI: 10.1002/14651858.CD003120.

21. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New England Journal of Medicine 1997; 336: 1216-1222.

22. Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine 2005; 142: 37-46.

23. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.

24. Aisen PS, Davis KL, Berg JD et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588-593.

25. Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.

26. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. The Cochrane Database of Systematic Reviews 2001; Issue 3. Art. No.: CD003160. DOI: 10.1002/14651858. CD003160.

27. Mulnard RA, Cotman CW, Kawas C et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. Journal of the American Medical Association 2000; 283: 1007-1015.

28. Thal LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. Estrogen levels do not correlate with improvement in cognition. Archives of Neurology 2003; 60: 209-212.

29. Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone replacement therapy to maintain cognitive function in women with dementia. The Cochrane Database of Systematic Reviews 2002; Issue 3. Art. No.: CD003799. DOI: 10.1002/14651858.CD003799.

30. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Journal of the American Medical Association 2003; 289: 2651-2662.

31. Wei, He, Wang. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of AD. J Neural Transm 2007.

32. Petersen RC. Mild cognitive impairment. Continuum Lifelong Learning Neurol 2007; 13(2): 15-38.

33. Black S, Roman GC, Geldmacher DS et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330.

34. Wilkinson D, Doody R, Helme R et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-486.

35. Craig D, Birks J. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004; Issue 2. Art. No.: CD004744. DOI: 10.1002/14651858.CD004744.pub2.

36. Craig D, Birks J. Galantamine for vascular cognitive impairment. The Cochrane Database of Systematic Reviews 2006; Issue 1. Art. No.: CD004746. DOI: 10.1002/14651858.CD004746.pub2.

37. Rands G, Orrel M, Spector A, Williams P. Aspirin for vascular dementia. The Cochrane Database of Systematic Reviews 2000; Issue 4. Art. No.: CD001296. DOI: 10.1002/14651858.CD001296.

38. Sha MC, Callahan CM. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer’s Disease and Associated Disorders 2003; 17: 46-54.

39. Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T.The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. Journal of Neurological Science 2000; 175: 116-123.

40. Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162(18): 2046-2052.

41. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology 2004; 17: 164-171.

42. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 2004; 351: 2509-2518.

43. McKeith IG, Grace JB, Walker Z, Byrne EJ, Wilkinson D, Stevens T, Perry EK. Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial. International Journal of Geriatric Psychiatry 2000; 15: 387-392.

44. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. European Neurology 2003; 49: 13-19.

45. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172: 400-408.

46. McKeith IG, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurology 2005; 4: 735-742.

47. Gustavson AR, Cummings JL. Assessment and Treatment of Neuropsychiatric Symptoms in Alzheimer’s disease. In: Richter RW, Richter ZR (Eds). Alzheimer’s Disease. A Physician’s Guide to Practical Management. New Jersey: Humana Press 2004: 371–385.

48. Trinh NH, Hoblyn J., Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. Journal of the American Medical Association 2003; 289: 210-216.

49. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. The Cochrane Database of Systematic Reviews 2006; Issue 1. Art. No.: CD001747. DOI: 10.1002/14651858.CD001747.pub3.

50. O’Brien JT, Ballard CG. Treating behavioural and psychological signs in Alzheimer's disease (editorial). British Medical Journal 1999; 319: 138-139.

51. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. New England Journal of Medicine 2005; 353: 2335-2341.

52. McKeith IG, Fairbairn AF, Perry RH, Thompson P, Perry EK. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal 1992; 305: 673-678.